- Home
- RYAM vs YMAB Comparison
RYAM vs YMAB Comparison
Compare RYAM & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYAM
- YMAB
- Stock Information
- Founded
- RYAM 1926
- YMAB 2015
- Country
- RYAM United States
- YMAB United States
- Employees
- RYAM N/A
- YMAB N/A
- Industry
- RYAM Paper
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- RYAM Basic Materials
- YMAB Health Care
- Exchange
- RYAM Nasdaq
- YMAB Nasdaq
- Market Cap
- RYAM 580.7M
- YMAB 482.4M
- IPO Year
- RYAM N/A
- YMAB 2018
- Fundamental
- Price
- RYAM $7.47
- YMAB $8.28
- Analyst Decision
- RYAM Buy
- YMAB Strong Buy
- Analyst Count
- RYAM 1
- YMAB 10
- Target Price
- RYAM $12.00
- YMAB $21.00
- AVG Volume (30 Days)
- RYAM 416.6K
- YMAB 303.4K
- Earning Date
- RYAM 11-05-2024
- YMAB 11-08-2024
- Dividend Yield
- RYAM N/A
- YMAB N/A
- EPS Growth
- RYAM N/A
- YMAB N/A
- EPS
- RYAM N/A
- YMAB N/A
- Revenue
- RYAM $1,630,290,000.00
- YMAB $84,553,000.00
- Revenue This Year
- RYAM $0.95
- YMAB $6.46
- Revenue Next Year
- RYAM $4.10
- YMAB $20.68
- P/E Ratio
- RYAM N/A
- YMAB N/A
- Revenue Growth
- RYAM N/A
- YMAB N/A
- 52 Week Low
- RYAM $3.15
- YMAB $6.29
- 52 Week High
- RYAM $10.28
- YMAB $20.90
- Technical
- Relative Strength Index (RSI)
- RYAM 30.02
- YMAB 25.63
- Support Level
- RYAM $7.21
- YMAB $9.31
- Resistance Level
- RYAM $8.62
- YMAB $11.10
- Average True Range (ATR)
- RYAM 0.31
- YMAB 0.72
- MACD
- RYAM -0.12
- YMAB -0.09
- Stochastic Oscillator
- RYAM 21.21
- YMAB 7.35
About RYAM Rayonier Advanced Materials Inc.
Rayonier Advanced Materials Inc manufactures high-purity cellulose derived from wood. Also known as cellulose specialties, the company's products are used in a variety of applications, including cigarette filters, liquid crystal displays, paints, pharmaceuticals, and food. The company operates in the reportable segments of High Purity Cellulose, Paperboard, High-Yield Pulp, and Corporate and Other. The key revenue is derived from the High Purity Cellulose segment. Geographically, it derives a majority of revenue from the United States.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.